EligibleTrials
Drugs & treatments › IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells

IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells: clinical trials recruiting now

Fewer than 3 recruiting trials found.

1
Recruiting trials
15
Conditions studied
1
US states with sites
1
Countries

Phase breakdown

Phase 1 1

Conditions being studied

ConditionTrials
Acral Melanoma1
Adrenocortical Carcinoma1
Breast Cancer1
Head and Neck Squamous Cell Carcinoma1
Lung Adenocarcinoma1
Lung cancer1
Melanoma1
Metastatic Malignant Solid Neoplasm1
Metastatic Melanoma1
Neuroendocrine Tumors1
Pancreatic Neuroendocrine Tumor1
Pancreatic cancer1
Paraganglioma1
Pathologic Stage IIIC Cutaneous Melanoma AJCC v81
Pathologic Stage IV Cutaneous Melanoma AJCC v81

Recruiting trials involving IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells

Common questions

How many recruiting trials involve IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells?

1 recruiting trial across 15 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.